In recent years, the onset of ovarian cancer has trended towards younger patients, and the malignancy of this cancer has also increased.1, 2 Many studies in recent years have demonstrated the presence of a subpopulation of cells in ovarian cancer tissue samples that are similar to embryonic stem cells and expresses high levels of CD44, CD133 and c‐Kit (CD117) markers. This evidence concerns the gene CD44 and ovarian carcinoma.